Journey Medical Corporation (Nasdaq:DERM), a pharmaceutical company with a focus on dermatological conditions, on Monday announced the launch and initial distribution of Emrosi, a 40 mg modified-release minocycline hydrochloride capsule, for the treatment of inflammatory lesions of rosacea in adults.
The product is available through specialty pharmacy chains.
Approved by the US Food and Drug Administration in November 2024, Emrosi is the lowest-dose oral minocycline available for rosacea treatment. Clinical trials demonstrated that Emrosi provides superior clinical outcomes compared to Oracea and placebo, while maintaining a comparable safety profile.
The first prescriptions of Emrosi have been filled.
Claude Maraoui, CEO of Journey Medical, said that the launch of Emrosi represents a major milestone for the company and reinforces its commitment to improving the quality of life for individuals with dermatological conditions.
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval
Alphyn doses first patient in Phase 2b trial of Zabalafin Hydrogel in Australia
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
Organon acquires US rights to TOFIDENCE from Biogen
Dupixent receives approval in Japan as first biologic for COPD treatment
Celltrion adds STEQEYMA to Costco Member Prescription Program
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories